

# Lukas M Pezawas

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3031874/publications.pdf>

Version: 2024-02-01

94  
papers

7,476  
citations

117625

34  
h-index

79698

73  
g-index

103  
all docs

103  
docs citations

103  
times ranked

9625  
citing authors

#	ARTICLE	IF	CITATIONS
1	5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression. <i>Nature Neuroscience</i> , 2005, 8, 828-834.	14.8	1,860
2	The Brain-Derived Neurotrophic Factor val66met Polymorphism and Variation in Human Cortical Morphology. <i>Journal of Neuroscience</i> , 2004, 24, 10099-10102.	3.6	807
3	Neural mechanisms of genetic risk for impulsivity and violence in humans. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 6269-6274.	7.1	793
4	Variation in DISC1 affects hippocampal structure and function and increases risk for schizophrenia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 8627-8632.	7.1	479
5	Prevalence and burden of bipolar disorders in European countries. <i>European Neuropsychopharmacology</i> , 2005, 15, 425-434.	0.7	282
6	Widespread Reductions of Cortical Thickness in Schizophrenia and Spectrum Disorders and Evidence of Heritability. <i>Archives of General Psychiatry</i> , 2009, 66, 467.	12.3	235
7	The suppressive influence of SMA on M1 in motor imagery revealed by fMRI and dynamic causal modeling. <i>NeuroImage</i> , 2008, 40, 828-837.	4.2	219
8	Evidence of biologic epistasis between BDNF and SLC6A4 and implications for depression. <i>Molecular Psychiatry</i> , 2008, 13, 709-716.	7.9	216
9	Is Gray Matter Volume an Intermediate Phenotype for Schizophrenia? A Voxel-Based Morphometry Study of Patients with Schizophrenia and Their Healthy Siblings. <i>Biological Psychiatry</i> , 2008, 63, 465-474.	1.3	179
10	Buprenorphine versus methadone maintenance for the treatment of opioid dependence. <i>Addiction</i> , 1999, 94, 1337-1347.	3.3	144
11	Heritability of Brain Morphology Related to Schizophrenia: A Large-Scale Automated Magnetic Resonance Imaging Segmentation Study. <i>Biological Psychiatry</i> , 2008, 63, 475-483.	1.3	134
12	Impact of interacting functional variants in COMT on regional gray matter volume in human brain. <i>NeuroImage</i> , 2009, 45, 44-51.	4.2	120
13	fMRI measurements of amygdala activation are confounded by stimulus correlated signal fluctuation in nearby veins draining distant brain regions. <i>Scientific Reports</i> , 2015, 5, 10499.	3.3	104
14	Reduced default mode network suppression during a working memory task in remitted major depression. <i>Journal of Psychiatric Research</i> , 2015, 64, 9-18.	3.1	99
15	Allelic Variation in RGS4 Impacts Functional and Structural Connectivity in the Human Brain. <i>Journal of Neuroscience</i> , 2007, 27, 1584-1593.	3.6	98
16	Influence of escitalopram treatment on 5-HT1A receptor binding in limbic regions in patients with anxiety disorders. <i>Molecular Psychiatry</i> , 2009, 14, 1040-1050.	7.9	87
17	Relationship of suicide rates to economic variables in Europe: 2000â€“2011. <i>British Journal of Psychiatry</i> , 2014, 205, 486-496.	2.8	86
18	In vivo 123 I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol. <i>Psychopharmacology</i> , 1999, 141, 175-181.	3.1	82

#	ARTICLE	IF	CITATIONS
19	Receptor and Transporter Imaging Studies in Schizophrenia, Depression, Bulimia and Tourette's Disorder—Implications for Psychopharmacology-. World Journal of Biological Psychiatry, 2002, 3, 133-146.	2.6	80
20	Imaging genetics of mood disorders. Neurolmage, 2010, 53, 810-821.	4.2	80
21	The Spectral Diversity of Resting-State Fluctuations in the Human Brain. PLoS ONE, 2014, 9, e93375.	2.5	76
22	Actigraphy in Patients with Seasonal Affective Disorder and Healthy Control Subjects Treated with Light Therapy. Biological Psychiatry, 2005, 58, 331-336.	1.3	69
23	Cerebral CT findings in male opioid-dependent patients: Stereological, planimetric and linear measurements. Psychiatry Research - Neuroimaging, 1998, 83, 139-147.	1.8	68
24	Multi-subject analyses with dynamic causal modeling. Neurolmage, 2010, 49, 3065-3074.	4.2	61
25	Additive Gene-Environment Effects on Hippocampal Structure in Healthy Humans. Journal of Neuroscience, 2014, 34, 9917-9926.	3.6	59
26	Natural course and burden of bipolar disorders. International Journal of Neuropsychopharmacology, 2003, 6, 145-154.	2.1	56
27	Fully exploratory network independent component analysis of the 1000 functional connectomes database. Frontiers in Human Neuroscience, 2012, 6, 301.	2.0	55
28	Physical Exercise Counteracts Genetic Susceptibility to Depression. Neuropsychobiology, 2015, 71, 168-175.	1.9	54
29	Altered resting-state functional connectome in major depressive disorder: a mega-analysis from the PsyMRI consortium. Translational Psychiatry, 2021, 11, 511.	4.8	51
30	Opioid Addiction Changes Cerebral Blood Flow Symmetry. Neuropsychobiology, 2002, 45, 67-73.	1.9	49
31	Relationship of suicide rates with climate and economic variables in Europe during 2000–2012. Annals of General Psychiatry, 2016, 15, 19.	2.7	48
32	Prefrontal networks dynamically related to recovery from major depressive disorder: a longitudinal pharmacological fMRI study. Translational Psychiatry, 2019, 9, 64.	4.8	43
33	Outpatient Opiate Detoxification Treatment with Buprenorphine. European Addiction Research, 1998, 4, 198-202.	2.4	42
34	Recurrent brief depressive disorder reinvestigated: a community sample of adolescents and young adults. Psychological Medicine, 2003, 33, 407-418.	4.5	37
35	Oppositional COMT Val158Met effects on resting state functional connectivity in adolescents and adults. Brain Structure and Function, 2016, 221, 103-114.	2.3	31
36	Receptor Test (Pupillary Dilatation after Application of 0.01% Tropicamide Solution) and Determination of Central Nervous Activation (Fourier Analysis of Pupillary Oscillations) in Patients with Alzheimer's Disease. Neuropsychobiology, 1999, 40, 40-46.	1.9	29

#	ARTICLE	IF	CITATIONS
37	The genetic blueprint of major depressive disorder: Contributions of imaging genetics studies. World Journal of Biological Psychiatry, 2011, 12, 474-488.	2.6	29
38	Is there a personalized medicine for mood disorders?. European Archives of Psychiatry and Clinical Neuroscience, 2010, 260, 121-126.	3.2	25
39	On the relationship of first-episode psychosis to the amphetamine-sensitized state: a dopamine D2/3 receptor agonist radioligand study. Translational Psychiatry, 2020, 10, 2.	4.8	25
40	A Longitudinal View of Triggers and Thresholds of Suicidal Behavior in Depression. Journal of Clinical Psychiatry, 2002, 63, 866-873.	2.2	25
41	Efficacy, cardiac safety and tolerability of sertindole: a drug surveillance. International Clinical Psychopharmacology, 2000, 15, 207-214.	1.7	23
42	Imaging genetics: Progressing by leaps and bounds. NeuroImage, 2010, 53, 801-803.	4.2	23
43	Recurrent brief depression revisited. International Review of Psychiatry, 2005, 17, 63-70.	2.8	22
44	Neuroplasticity and memory formation in major depressive disorder: An imaging genetics perspective on serotonin and BDNF. Restorative Neurology and Neuroscience, 2014, 32, 25-49.	0.7	22
45	Mirtazapine in recurrent brief depression. International Clinical Psychopharmacology, 1998, 13, 39-40.	1.7	21
46	Fluoxetine treatment in patients with recurrent brief depression. International Clinical Psychopharmacology, 2001, 16, 221-226.	1.7	21
47	Affective and inflammatory responses among orchestra musicians in performance situation. Brain, Behavior, and Immunity, 2014, 37, 23-29.	4.1	21
48	Platelet Serotonin Transporter Function Predicts Default-Mode Network Activity. PLoS ONE, 2014, 9, e92543.	2.5	19
49	Brain morphometry and connectivity differs between adolescent and adult onset major depressive disorder. Depression and Anxiety, 2022, 39, 387-396.	4.1	18
50	Recurrent brief depression—past and future. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2003, 27, 75-83.	4.8	17
51	A multivariate approach linking reported side effects of clinical antidepressant and antipsychotic trials to in vitro binding affinities. European Neuropsychopharmacology, 2014, 24, 1463-1474.	0.7	16
52	Parsing the clinical phenotype of depression: the need to integrate brief depressive episodes. Acta Psychiatrica Scandinavica, 2007, 115, 221-228.	4.5	15
53	A highly parallelized framework for computationally intensive MR data analysis. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2012, 25, 313-320.	2.0	14
54	Imaging genetics: implications for research on variable antidepressant drug response. Expert Review of Clinical Pharmacology, 2010, 3, 471-489.	3.1	13

#	ARTICLE	IF	CITATIONS
55	Successful Treatment of Recurrent Brief Depression with Reboxetine - A Single Case Analysis. Pharmacopsychiatry, 2002, 35, 75-76.	3.3	12
56	Midday and nadir salivary cortisol appear superior to cortisol awakening response in burnout assessment and monitoring. Scientific Reports, 2018, 8, 9151.	3.3	11
57	MET BDNF protects against morphological S allele effects of 5-HTTLPR. Molecular Psychiatry, 2008, 13, 654-654.	7.9	9
58	rs6295 [C]-Allele Protects Against Depressive Mood in Elderly Endurance Athletes. Journal of Sport and Exercise Psychology, 2015, 37, 637-645.	1.2	8
59	The use of the antioxidant tirilazad mesylate in human liver transplantation: is there a therapeutic benefit?. Intensive Care Medicine, 1999, 25, 616-619.	8.2	6
60	Neural Mechanisms of Genetic Risk for Impulsivity and Violence in Humans. Focus (American Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 542	0.8	6
61	Neurobiological predictors for clinical trajectories in fully remitted depressed patients. Depression and Anxiety, 2021, 38, 447-455.	4.1	6
62	Disrupted relationship between blood glucose and brain dopamine D2/3 receptor binding in patients with first-episode schizophrenia. NeuroImage: Clinical, 2021, 32, 102813.	2.7	5
63	Relationship between Power Spectra of the Awake EEG and Psychomotor Activity Patterns Measured by Short-Term Actigraphy. Neuropsychobiology, 2003, 48, 176-181.	1.9	4
64	New perspectives on techniques for the clinical psychiatrist: Brain stimulation, chronobiology and psychiatric brain imaging. Psychiatry and Clinical Neurosciences, 2008, 62, 627-637.	1.8	2
65	P.2.083 Sertindole in clinical practice. European Neuropsychopharmacology, 1997, 7, S218.	0.7	1
66	Paroxetine in panic disorder with agoraphobia. International Journal of Psychiatry in Clinical Practice, 2001, 5, 279-281.	2.4	1
67	Recurrent brief depression as an indicator of severe mood disorders. , 2005, , 109-130.		1
68	INNOPSY 2007. International Journal of Psychiatry in Clinical Practice, 2007, 11, 4-24.	2.4	1
69	Remitted major depression is related to increased functional coupling between ventral striatum and cortical regions in resting state fMRI. European Psychiatry, 2011, 26, 948-948.	0.2	1
70	Brain-derived neurotrophic factor: a peripheral biomarker for major depressive disorder and antidepressant efficacy?. Personalized Medicine, 2011, 8, 115-117.	1.5	1
71	Serotonin Transporter Linked Polymorphic Region: From Behavior to Neural Mechanisms. Biological Psychiatry, 2015, 78, 522-524.	1.3	1
72	Variability of Antidepressant Drug Response. , 2016, , 81-100.		1

#	ARTICLE	IF	CITATIONS
73	Mirtazapine in recurrent brief depression (RBD). Biological Psychiatry, 1997, 42, 242S.	1.3	0
74	Nimodipine in a lithium non-responder with bipolar I disorder. Biological Psychiatry, 1997, 42, 251S.	1.3	0
75	P.1.162 Mirtazapine in recurrent brief depression (RBD). European Neuropsychopharmacology, 1997, 7, S186-S187.	0.7	0
76	BDNF X SERT interactions: Implication for depression. International Journal of Psychophysiology, 2008, 69, 190.	1.0	0
77	P.1.e.011 Fronto-limbic interaction of working memory and emotion in the medial prefrontal cortex. European Neuropsychopharmacology, 2010, 20, S294.	0.7	0
78	Biological alterations during remission of major depressive disorder. European Psychiatry, 2011, 26, 633-633.	0.2	0
79	Peripheral serotonin uptake is related to neural activation in the cingulate cortex. European Psychiatry, 2011, 26, 684-684.	0.2	0
80	Increased functional coupling between basalganglia and cingulate and prefrontal cortex during resting state conditions in remitted major depressive disorder. European Psychiatry, 2011, 26, 915-915.	0.2	0
81	Multimodal imaging of an astrocytoma affecting the amygdalar region. European Psychiatry, 2011, 26, 924-924.	0.2	0
82	Increased coupling of resting state activity between amygdala and cortical emotion processing regions in remitted major depressive disorder. European Psychiatry, 2011, 26, 931-931.	0.2	0
83	P.1.033 Serotonin uptake in platelets predicts neural activation in the cingulate cortex. European Neuropsychopharmacology, 2011, 21, S27.	0.7	0
84	P.2.c.020 Synthesising evidence in clinical psychopharmacology and beyond: a re-examination of published meta-analyses. European Neuropsychopharmacology, 2011, 21, S394-S395.	0.7	0
85	Genetics and Emotion. , 2013, , .		0
86	Imaging Genetics in Humans. , 2017, , 361-369.		0
87	Will atypical antipsychotics play a role in phase prophylaxis?. Pharmacopsychiatry, 2005, 38, .	3.3	0
88	Recurrent Brief Depression. , 2010, , 1142-1142.		0
89	Increased functional activation and connectivity in the working memory network in remitted major depressive disorder. Frontiers in Human Neuroscience, 0, 5, .	2.0	0
90	Genetic Regulation of Emotion Brain Circuitries. Frontiers in Neuroscience, 2011, , 75-96.	0.0	0

#	ARTICLE	IF	CITATIONS
91	Recurrent Brief Depressive Disorder. , 2015, , 1456-1459.		0
92	Imaging genetics in depression. , 2019, , 235-246.		0
93	Disrupted Relationship between Blood Glucose Levels and Dopamine D <sub>2/3</sub> Receptor Availability in Patients with First-Episode Schizophrenia. A Case-Control PET-Imaging Study. SSRN Electronic Journal, 0, , .	0.4	0
94	Nutritional status, ICU duration and ICU mortality in lung transplant recipients. Intensive Care Medicine, 1996, 22, 1179-1185.	8.2	0